menu Menu Search
What are you looking for? close
RCVS Registered: 7025700
Run by a qualified team of Vets
First Class Delivery only £3.99
Next Day Delivery available
30mg Daxocox Tablets for Dogs - Pack of 4
View Larger

30mg Daxocox Tablets for Dogs - Pack of 4



Daxocox 30mg is a highly effective analgesic that is administered orally. It reduces pain in dogs with osteoarthritis, or degenerative joint disease, and can be given once a week to provide consistent pain control. VETERINARY PRESCRIPTION REQUIRED

Product Features

add remove
  • Pack Size: - Pack of 4
  • Target Animal: - Dog (Canine)
  • Related Condition: - Treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.
  • Pet Prescription Required?: - Yes
  • Active Ingredient: - Enflicoxib
  • Product Name: - 30mg Daxocox for Dogs

More Information

add remove


30mg Daxocox tablets for dogs - Pack of 4

Daxocox contains the active ingredient Enflicoxib. They are brown, round and convex tablets. These easy-to-administer tablets are specially formulated for dogs, and can be given once a week to provide consistent pain control with no need for daily dosing. Daxocox is a non-steroidal anti-inflammatory drug (NSAID) and can be given once a week to provide consistent pain control.

Indications for use
Daxocox is used for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs. Do not use in animals suffering from gastrointestinal disorders, protein or blood losing enteropathy or haemorrhagic disorders. Do not use Daxocox in cases of impaired renal or hepatic function. Do not use in cases of cardiac insufficiency. Do not use in pregnant or lactating dogs.

Do not use Daxocox in animals intended for breeding purposes. Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Do not use in cases of known hypersensitivity to sulphonamides. Do not use in any dehydrated, hypovolemic or hypotensive animal, as there is a potential risk of increased renal toxicity. Special warnings for each target species Do not administer other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or glucocorticoids concurrently or within 2 weeks of the last administration of this veterinary medicinal product. Special precautions for use in animals Since the safety of the medicinal product has not been fully demonstrated in very young animals, careful monitoring is advised during the treatment of young dogs aged less than 6 months. The active metabolite of enflicoxib exhibits an extended plasma half-life due to its low rate of elimination. Use Daxocox under strict veterinary monitoring where there is a risk of gastrointestinal ulceration, or if the animal previously displayed intolerance to NSAIDs. Special precautions to be taken by the person administering the veterinary medicinal product to animals This veterinary medicinal product can cause hypersensitivity (allergic) reactions. People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. Some NSAIDs may be harmful for the unborn child, especially during the third trimester of pregnancy. Pregnant women should administer this veterinary medicinal product with care. Ingestion of this veterinary medicinal product may be harmful, especially for children, and prolonged pharmacological effects leading to e.g. gastrointestinal disorders may be observed. To avoid accidental ingestion, administer the tablet to the dog immediately after removal from the blister packaging and do not split or crush tablets. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Adverse reactions (frequency and seriousness) Vomiting, soft faeces and/or diarrhoea have been commonly reported in clinical trials, but most cases recovered without treatment. Apathy, loss of appetite or haemorrhagic diarrhoea have been reported in uncommon cases. Gastrointestinal ulceration has been reported in uncommon cases. Elevated blood urea and serum cholesterol levels were observed in healthy, young dogs at the recommended dose in a laboratory safety study. In case of adverse reactions the use of the veterinary medicinal product should be stopped and general supportive therapy, as for clinical overdose with NSAIDs, should be applied until complete resolution of the signs. Particular attention should be paid to maintain haemodynamic status. Gastrointestinal protectants and parenteral fluids, as appropriate, may be required for animals that experience gastrointestinal or renal adverse reactions. Use during pregnancy, lactation or lay Laboratory studies in rats and rabbits have shown evidence of foetotoxic effects at maternally toxic doses. The safety of this veterinary medicinal product has not been established during pregnancy, lactation or reproduction in the target species. Do not use Daxocox in pregnant, lactating or breeding dogs. Interaction with other medicinal products and other forms of interaction No drug-interaction studies have been performed. In common with other NSAIDs, this veterinary medicinal product should not be administered simultaneously with other NSAIDs or glucocorticoids. Animals should be carefully monitored if this veterinary medicinal product is administered simultaneously with an anticoagulant. Enflicoxib is highly bound to plasma proteins and may compete with other highly bound substances, such that concomitant administration may result in toxic effects. Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse reactions. To avoid such adverse reactions when this veterinary medicinal product is to be administered in replacement to another NSAID, ensure an appropriate treatment-free period before administering the first dose. The treatmentfree period should, however, consider the pharmacology of the medicinal products previously used. Concurrent administration of potentially nephrotoxic veterinary medicinal products should be avoided. Amounts to be administered and administration route Oral use.

Dosing interval is ONCE PER WEEK

Legal Category
Daxocox is a POM-V (Veterinary Pet Prescription Required)